ERBB2 and ductal breast carcinoma in situ: Since then, the National Comprehensive Cancer Network (NCCN) has recommended ER-staining of DCIS to guide adjuvant ET recommendations [10], while progesterone receptor (PR) and HER2 status are currently not routinely used for DCIS decision making.